CAJ | 학술논문

目的：观察榄香烯联合NP化疗方案、沙利度胺以及化疗前24 h口服质子泵抑制剂（ PPI）综合治疗晚期非小细胞肺癌的疗效。方法将136例晚期非小细胞肺癌患者随机分为对照组和综合治疗组，各68例。综合治疗组给予长春瑞滨、顺铂化疗及口服沙利度胺、静脉滴注榄香烯注射液，化疗前24 h口服质子泵抑制剂（ PPI）等治疗；对照组给予长春瑞滨、顺铂化疗。21天为1个周期，2～3个周期后评价疗效。结果综合治疗组有效率（ CR＋PR）为76．5％（52／68），明显高于对照组48．5％（33／68）；综合治疗组1年、2年、3年生存率分别为88．2％、57．4％、33．8％，中位生存期为22个月；而对照组分别为60．3％、29．4％、13．2％，中位生存期为9个月。2组生存差异比较，有统计学意义（ P＜0．01）。KPS评分及体重变化综合治疗组明显好于对照组（ P＜0．01）。综合治疗组及对照组Ⅱ度及Ⅱ度以上胃肠道反应总发生率分别为16．2％（11／68）和47．1％（32／68），2组间差异有统计学意义（P＜0．01）。结论榄香烯联合NP化疗方案、沙利度胺以及化疗前24 h口服质子泵抑制剂（ PPI）综合治疗晚期非小细胞肺癌能明显提高患者近期治疗有效率和生存率，降低肿瘤耐药，提高化疗药物的疗效，增强机体免疫力，提高生存质量。
목적：관찰람향희연합NP화료방안、사리도알이급화료전24 h구복질자빙억제제（ PPI）종합치료만기비소세포폐암적료효。방법장136례만기비소세포폐암환자수궤분위대조조화종합치료조，각68례。종합치료조급여장춘서빈、순박화료급구복사리도알、정맥적주람향희주사액，화료전24 h구복질자빙억제제（ PPI）등치료；대조조급여장춘서빈、순박화료。21천위1개주기，2～3개주기후평개료효。결과종합치료조유효솔（ CR＋PR）위76．5％（52／68），명현고우대조조48．5％（33／68）；종합치료조1년、2년、3년생존솔분별위88．2％、57．4％、33．8％，중위생존기위22개월；이대조조분별위60．3％、29．4％、13．2％，중위생존기위9개월。2조생존차이비교，유통계학의의（ P＜0．01）。KPS평분급체중변화종합치료조명현호우대조조（ P＜0．01）。종합치료조급대조조Ⅱ도급Ⅱ도이상위장도반응총발생솔분별위16．2％（11／68）화47．1％（32／68），2조간차이유통계학의의（P＜0．01）。결론람향희연합NP화료방안、사리도알이급화료전24 h구복질자빙억제제（ PPI）종합치료만기비소세포폐암능명현제고환자근기치료유효솔화생존솔，강저종류내약，제고화료약물적료효，증강궤체면역력，제고생존질량。
Objective To observe the curative effects of comprehensive treatment of elemene,NP chemotherapy,thalido-mide and oral PPI 24 hours before chemotherapy for advanced non-small cell lung cancer(NSCLC).Methods 136 advanced non-small cell lung cancer patients were randomly divided into the control group and the comprehensive treatment group,each with 68 cases.The comprehensive treatment group were given elemene,thalidomide combined with navelbine,cisplatin chemotherapy, and oral PPI 24 hours before chemotherapy.The control group were given navelbine,cisplatin chemotherapy.21 days as a cycle, curative effects were evaluated after 2 or 3 cycles.Results Efficiency(CR +PR) of the comprehensive treatment group was 76.5%(252/68),which was obviously higher than that of the control group 48.5%(33/68).1-,2-,3-year survival rates of the comprehensive treatment group were 88.2%,57.4%,33.8%respectively,and those of the control group were 60.3%,29.4%, 13.2%respectively.The median survival time of the comprehensive treatment group and the control group were 22 months and 9 months respectively,there were significant differences(P<0.01).KPS score and weight change of the comprehensive treatment group were better than those of the control group(P<0.01).Incidence ofⅡdegree andⅡdegree above gastrointestinal reactions were 16.2%(11/68) and 47.1%(32/68),there were statistically significant difference(P<0.01).Conclusion Elemene,tha-lidomide combined with navelbine,cisplatin chemotherapy,and oral PPI 24 hours before chemotherapy can significantly improve short-term efficiency and survival rate of advanced non-small lung cancer patients,reduce the resistance of antineoplastic drugs, enhance curative effect of chemotherapeutic drugs,heighten the function of immune system of the body and improve the life quality of patients.